Prolonged bottle use and obesity at 5.5 years of age in US children

Rachel A Gooze1, Sarah E Anderson, Robert C Whitaker

  • 1Department of Public Health, Center for Obesity Research and Education, Temple University, Philadelphia, PA 19140, USA.

Insights

Prolonged bottle use in toddlers is linked to a higher risk of childhood obesity. Avoiding extended bottle use may be a strategy to prevent obesity in young children.

Area of Science:

  • Pediatrics
  • Public Health
  • Nutrition Science

Background:

  • Early childhood obesity is a growing public health concern.
  • Dietary habits and feeding practices in infancy and toddlerhood can influence long-term weight status.
  • Understanding risk factors for childhood obesity is crucial for developing effective prevention strategies.

Purpose of the Study:

  • To investigate the association between prolonged bottle use and the risk of developing obesity at 5.5 years of age.
  • To determine if continued bottle consumption beyond 24 months is a predictor of later obesity.
  • To provide evidence-based insights for pediatricians and parents regarding feeding practices.

Main Methods:

  • Analysis of data from 6750 US children in the Early Childhood Longitudinal Study, Birth Cohort.
  • Defined obesity as a body mass index (BMI) at or above the 95th percentile at 5.5 years.
  • Assessed prolonged bottle use based on parental report of bottle consumption at 24 months of age.

Main Results:

  • The prevalence of obesity at 5.5 years was 17.6%.
  • Children using a bottle at 24 months had a higher prevalence of obesity (22.9%) compared to those not using a bottle (16.1%).
  • Prolonged bottle use was significantly associated with an increased risk of obesity at 5.5 years (OR, 1.33; 95% CI, 1.05 to 1.68), even after adjusting for confounding factors.

Conclusions:

  • Prolonged bottle use is a significant risk factor associated with obesity in early childhood.
  • Limiting or avoiding bottle use beyond 24 months may contribute to the prevention of childhood obesity.
  • This finding highlights the importance of age-appropriate feeding practices for healthy weight development.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Stress Prevention and Stress Management Techniques IV01:26

Stress Prevention and Stress Management Techniques IV

Stress often leads to unhealthy habits like smoking, excessive drinking, and overeating, which offer short-term relief but ultimately increase long-term health risks. These behaviors create a cycle that temporarily lowers stress levels but can result in severe long-term health consequences. Breaking these habits is essential to reduce the risk of chronic diseases and improve overall well-being. Three primary changes that support better health include quitting smoking, reducing alcohol intake,...